Eva Lindskog, born in 1973, has more than 15 years of experience in senior positions within the Life Science industry, with a focus on bioprocessing, contract manufacturing, and analytical technologies. She currently works as Chief Commercial Officer at NanoTemper Technologies.

Lindskog has previously held senior roles at Sartorius, where she was responsible for the Fluid Management Technologies business area, as well as at Lonza and GE Healthcare Life Sciences (now Cytiva).

Eva Lindskog holds a Master of Science in Chemical Engineering and a PhD in Bioprocess Technology from KTH Royal Institute of Technology.

Andrea Ballagi, born in 1965, has nearly 30 years of experience in senior positions within the Life Science industry, with a focus on the commercialization of biotech products, international business development, and sales and marketing. She currently serves as Global Head of Market Development in Oncology at Olink Proteomics AB (now part of Thermo Fisher Scientific).

Ballagi has previously held several senior roles at Olink, where she built and led commercial teams in Europe and the Asia-Pacific region, as well as at IDEXX Laboratories, where she, among other roles, served as CEO of a Swedish subsidiary.

Andrea Ballagi is a physician, holds a PhD from the Ludwig Institute of Cancer Research in Uppsala, and an MBA from Uppsala University.

• "The Nomination Committee’s proposal for new board members is very welcome," says Peter Ehrenheim. "With Ballagi and Lindskog, the board’s expertise in bioprocessing and Life Science is significantly broadened and deepened. They will contribute to realizing the substantial market potential the company possesses."
• "Lindskog’s expertise in bioprocess technology and Ballagi’s experience in taking smaller Life Science companies through a scaling phase will provide important and much-needed contributions to Bio-Works in their respective areas," Ehrenheim adds.

The Bio-Works Nomination Committee for the 2026 Annual General Meeting has consisted of Elisabet Tunon, appointed by Swedia Invest AB, Erik Åfors, appointed by Calyptra AB, and Jonas Ahlén, appointed by Bonit Invest AB. The full motivated opinion from the Nomination Committee will be published in connection with the notice of the 2026 Annual General Meeting.

Contacts
For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Peter Ehrenheim, Chairman, e-mail: peter@farjsundet.se, phone: +46 (70) 667 5711.

About Bio-Works
Bio-Works enables Biotech companies to achieve their goals for purification of biomolecules. We support our customers, from laboratory research to commercial production, and together we implement efficient and robust solutions for bioprocessing. Our ambition is to be a trusted and dynamic partner in an industry characterized by growth and development.

Bio-Works’ headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Spotlight Stock Market ("BIOWKS"). For more information, visit www.bio-works.com.